0MR6.IL - Chr. Hansen Holding A/S
| Chiusura precedente | 514,40 |
| Aperto | 0,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 509,22 - 509,22 |
| Intervallo di 52 settimane | 360,20 - 604,40 |
| Volume | |
| Media Volume | 202.542 |
| Capitalizzazione | 67,015B |
| Beta (5 anni mensile) | 0,24 |
| Rapporto PE (ttm) | 38,67 |
| EPS (ttm) | 13,17 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | 7,04 (1,37%) |
| Data ex dividendo | 24 nov 2022 |
| Stima target 1A | N/D |
GlobeNewswireChr. Hansen Holding A/S Interim Report Q2 2022/23
April 13, 2023 – Company announcement no. 6 A strong first half supporting the full-year outlook Statement by CEO Mauricio Graber: “The strong results for Q2 confirm the attractiveness of the markets we serve in FC&E and H&N, and the resilience of our customer-focused business model. Organic growth came in higher than expected and reached 11%, driven by both pricing initiatives and volume growth. EBIT b.s.i. increased by 8% despite higher input costs and a less favorable product mix, leading to
- GlobeNewswire
Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. March 30, 2023 The proposed combination of Novozymes and Chr. Hansen has now been approved by each company’s respective shareholders, and with strong support from the shareholders the two biosolutions companies are now one step closer to uniting. The new company is expected
- GlobeNewswire
Resolutions passed at the Extraordinary General Meeting of Chr. Hansen Holding A/S
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. MARCH 30, 2023 – COMPANY ANNOUNCEMENT NO. 5 At the Extraordinary General Meeting of Chr. Hansen Holding A/S (“Chr. Hansen”) held on Thursday March 30, 2023, the following proposals as set out in detail in the convening notice were adopted: Resolution to adopt the implementation of a statutory merger of Chr. Hansen
- GlobeNewswire
Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. MARCH 30, 2023 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen had entered into a merger agreement to combine by way of a statutory merger of the two companies (the "Combination"). Reference is made to Chr. Hansen's company annou
- GlobeNewswire
Update on the combination of Novozymes and Chr. Hansen: U.S. antitrust regulation waiting period has expired, supporting the path to completion
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. MARCH 28, 2023 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies. Refer
- GlobeNewswire
Notice to convene Extraordinary General Meeting
MARCH 8, 2023 – ANNOUNCEMENT NO. 4 An Extraordinary General Meeting of Chr. Hansen Holding A/S will be held on Thursday, March 30, 2023, at 5:00 p.m. CEST at The Hangar – Clarion Hotel & Congress Copenhagen Airport, Ellehammersvej 20, DK-2770 Kastrup, Denmark. The notice to convene the Extraordinary General Meeting, including annex 1 “Articles of Association”, is enclosed. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +4
- GlobeNewswire
Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. March 8, 2023 – Company announcement no. 3 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen had entered into a merger agreement to combine by way of a statutory merger of the two companies
- GlobeNewswire
Novozymes and Chr. Hansen receive binding tax ruling that the proposed merger can be completed as a tax-exempt merger
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. JANUARY 24, 2023 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies (the
- GlobeNewswire
Chr. Hansen Holding A/S Interim Report Q1 2022/23
January 12, 2023 – Company announcement no. 1 Solid Q1 supports the outlook for 2022/23 Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased by 17% supported by the organic growth and exchange rates, leading to an EBIT margin b.s.i. of 24.7%. In light of the Q1 performance we maintain our underlying target for the year but update the outlook to refle
- GlobeNewswire
Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner
DECEMBER 12, 2022 – ANNOUNCEMENT NO. 13 Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. Please see attachment. CONTACT INFORMATION Novozymes:Investor RelationsTobias Cornelius Björklund+45 3077 8682tobb@novozymes.comChr. Hansen:Investor R
- GlobeNewswire
Manager’s transactions
December 9, 2022 – announcement no. 12 Shares received as a result of automatic reinvestment of dividends under short-term and long-term share-based incentive programs in Chr. Hansen Holding A/S administered by a third party. Please see attachment. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364 Cristina Rønde Hefting, Senior Investor Relations Manager, Tel: +45 4072 1224 Kathrine Westermann, Head of Media Re
- GlobeNewswire
Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S
NOVEMBER 23, 2022 – ANNOUNCEMENT NO. 11 Please see attachment. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364 Cristina Rønde Hefting, Senior Investor Relations Manager, Tel: +45 4072 1224Kathrine Westermann, Head of Media Relations, Tel: +45 2381 5595 Attachment No 11 Resolutions passed at Annual General Meeting of Chr. Hansen Holding AS final
- GlobeNewswire
Vesting of restricted share units
November 3, 2022 – announcement no. 10 Chr. Hansen Holding A/S has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in Chr. Hansen Holding A/S made by persons discharging managerial responsibilities in Chr. Hansen Holding A/S and/or persons closely related with them. Please see attachment. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364 C
- GlobeNewswire
Notice to convene the Annual General Metting 2022
OCTOBER 27, 2022 – ANNOUNCEMENT NO. 9 The Annual General Meeting of Chr. Hansen Holding A/S will be held on Wednesday, November 23, 2022, at 4:00 p.m. CET at Scandic Falkoner, Falkoner Alle 9, 2000 Frederiksberg, Denmark. The notice to convene the Annual General Meeting, including annex 1 “Articles of Association” and annex 2 “Description of the candidates for the Board of Directors”, is enclosed. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & In
- GlobeNewswire
Chr. Hansen Annual Report 2021/22
October 12, 2022 – Company announcement no. 7 Statement by CEO Mauricio Graber: “We have delivered a solid financial performance despite a volatile macroeconomic and geopolitical environment. Organic growth reached 9%, EBIT margin b.s.i. 26.8%, and the free cash flow b.a.s.i. ended at EUR 172 million in line with our latest guidance. Looking into 2022/23 we will continue to adapt to a changing business environment for both us and our customers and aim to deliver solid organic revenue and EBIT gr
- GlobeNewswire
Chr. Hansen Holding A/S - Major shareholder announcement from APG Asset Management N.V.
Company announcement no. 6/2022 August 2, 2022 Please see attachment. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364 Sanne Seyer-Hansen, Head of Media Relations, Tel: +45 6038 6207 About Chr. Hansen Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely position
- GlobeNewswire
Chr. Hansen Holding A/S Interim Report Q3 2021/22
Company announcement no. 05/2022 July 7, 2022 Solid Q3 in an uncertain macroeconomic environment Statement by CEO Mauricio Graber: “The execution of our strategy to differentiate as a focused microbial and fermentation technology company continued to deliver solid results with 9% organic growth for the third quarter 2021/22, equal to 13% growth in EUR terms. Our inflation-driven pricing measures started to contribute positively during Q3, while volume growth slowed down as expected following the